Which stocks are best to buy now? According to Top Wall Street Analysts, this one stock listed below is a Strong Buy. It received a new Buy rating recently and has a significant upside of 350%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.
Neurogene (NGNE) – Neurogene is a clinical-stage biotech company developing gene therapies for rare neurological disorders. Today, William Blair analyst Sami Corwin maintained a Buy rating on the stock, saying the company is making steady progress in its key trial and staying on track with timelines. He added that early data looks very strong, with lasting benefits in patients, and believes the therapy could become a leading treatment with good launch potential. In the last three months, all six Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 350%.
Who Are the Top Analysts?
TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.